ViiV Healthcare has reported new positive results from the Phase III GEMINI 1 and 2 clinical trials evaluating Dovato for the treatment of HIV-1 infection.

Dovato is a two-drug regimen of dolutegravir and lamivudine.

Data at 96 weeks showed non-inferior efficacy of the two-drug regimen compared to a three-drug regimen of dolutegravir and tenofovir disoproxil fumarate/emtricitabine (TDF/FTC).

Pooled analysis revealed that 86% of subjects on Dovato had HIV-1 RNA <50 copies per millilitre (c/mL) compared to 90% treated with the three-drug regimen.

Across both trials, 1.5% of patients on dolutegravir and lamivudine regimen and 1% in the dolutegravir plus TDF/FTC arm reached protocol-defined virologic withdrawal criteria up to week 96.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Patients with virologic failure did not experience treatment-emergent resistance, the company noted.

Response rates for viral suppression were observed to be similar in both treatment groups of patients having a baseline viral load of more than 100,000 copies per millilitre of blood plasma.

Data from the pooled study population found nasopharyngitis, diarrhoea, and headache to be the most common drug-related adverse events (AEs) in both groups.

However, drug-related AEs were less frequent in the Dovato arm compared to the three-drug regimen arm.

These findings were consistent with week 48 data, where dolutegravir plus lamivudine met the primary endpoint of non-inferiority in both GEMINI 1 and 2 studies.

ViiV Healthcare Global Research and Medical Strategy head Kimberly Smith said: “The GEMINI 1 and 2 studies have already changed the way we treat people living with HIV, with the combination of dolutegravir plus lamivudine allowing many people to reduce the number of medicines they take and manage their HIV without a third antiretroviral treatment.

“The week 96 data further demonstrate the durable efficacy and tolerability of dolutegravir plus lamivudine.”

Earlier this year, Dovato received US regulatory approval for treating HIV-1 in adults without any antiretroviral therapy history or known resistance to dolutegravir or lamivudine.

The two-drug regimen also secured European authorisation to treat HIV-1 infection in adults and adolescents aged above 12 years, weighing at least 40kg, with no known or suspected resistance to lamivudine.